Q2 2021

Filed Aug 9, 2021 · 10-Q · 40 days after period end · 0001564590-21-042652

Q2 2021 · 10-Q

Revenue

$22.04M

+33.0% vs Q2 2020

Net Income

-$57.64M

N/M vs Q2 2020

EPS Diluted

-$1.36

N/M vs Q2 2020

Operating Income-$52,226,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2021	Q2 2020	Q2 2019	Q2 2018
Revenue	$22.04M	$16.57M	$7.88M	$40.03M
Net Income	-$57.64M	-$33.76M	-$1.46M	$10.59M
EPS Diluted	-$1.36	-$0.91	-$0.04	$0.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR